Drug: Nivolumab (Opdivo, Bristol-Myers Squibb)
Status: Granted accelerated approval for the treatment of adult and pediatric (12 years of age or older) patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed after treatment with fluoropyrimidine, oxaliplatin and irinotecan
Significant Information:
- Recommended dosage of 240 mg administered as an IV infusion over 60 minutes every two weeks